Transforming Neuropsychiatric Therapeutics with Dr. Sam Clark, CEO of Terran Biosciences

This episode of the From Lab to Launch podcast, brought to you by Qualio, features Dr. Sam Clark, CEO of Terran Biosciences. With a background in neurosciences from MIT and an MD and PhD from Columbia University, Dr. Clark shares his journey from academia to leading a pioneering company in neuropsychiatric therapeutics. He discusses the challenges and innovations in the development and supply of GMP psychedelic compounds, highlighting how these substances are making significant strides toward transforming mental health treatment. Dr. Clark also explores Terran Biosciences' approach to overcoming drug development hurdles, emphasizing quality management and patent strategies to ensure the delivery of affordable, effective treatments. His insights offer a glimpse into the future of psychedelics in mainstream medicine and the broader implications for treating various disorders beyond mental health.https://terranbiosciences.com/ Dr. Sam Clark's LinkedIn: https://www.linkedin.com/in/sam-clark-md-phd-133139199/ 00:00 Welcome to From Lab to Launch!00:40 Introducing Dr. Sam Clark and Terran Biosciences01:23 Dr. Clark's Journey: From Academia to Neuropsychiatric Therapeutics02:48 The Renaissance of Psychedelic Therapeutics04:36 Challenges and Innovations in Drug Development08:36 Quality Management at Terran Biosciences10:23 The Future of Psychedelics in Mainstream Medicine12:46 Expanding Beyond Neuropsychiatry: Terran's Broader Impact14:02 Navigating Innovation and Ethics in Patenting17:48 Advice for Aspiring Scientists and Innovators20:42 Dr. Clark's Personal Inspirations and Closing Thoughts22:21 How to Follow Dr. Clark and Terran Biosciences23:00 Wrapping Up and How to Engage with From Lab to LaunchQualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez